What question did this study set out to answer?

The aim is to understand treatment choices and the impact of anemia on patients with myelofibrosis, as well as quality of life.

Real-world treatment landscape and disease burden of myelofibrosis in Taiwan, South Korea, Japan, and Canada

View Full Paper

Ask AI

Bookmark

The aim is to understand treatment choices and the impact of anemia on patients with myelofibrosis, as well as quality of life.
Data was collected from a cross-sectional survey involving hematologists and patients in Taiwan, South Korea, Japan, and Canada.
A total of 86 physicians and 283 patients took part in the Adelphi MF I Disease Specific Programme™ from May 2024 to January 2025.
83-90% of physicians prioritized improving hemoglobin levels, while 84-92% emphasized reducing symptom severity.
99% of first-line treatments for patients with myelofibrosis were ruxolitinib, with mean dosages of 19.1 mg/day for those with anemia and 25.2 mg/day for those without.
71% of patients expressed dissatisfaction with transfusion hospital visits, and 59% were dissatisfied with the number and severity of side effects.

No takes yet. Share an insight, caveat, or question.

Cross-sectional survey explores treatment choices and burden of myelofibrosis in multiple countries, highlighting critical areas for improvement.

Kanda et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Cross-sectional survey explores treatment choices and burden of myelofibrosis in multiple countries, highlighting critical areas for improvement.